Reference 2021-59

REF: 2021-59               

Subject: CPAP / Ventilator           

 

Request:

I’m writing to you under the Freedom of Information Act (2000) to request information on the usage of certain types of Ventilator within your Trust, based on the models acquired during the ventilator challenge specifically relating to: 

 

·  the Penlon ventilators, 

·  The Breas Ventilators,

·  The Smiths Medical Ventilators,

·  and the CPAP non-invasive units. 

 

I’d like to know, if possible: 

 

·  how many of the various invasive models were used within your trust vs how many were ordered (the Penlon units being the most important with regards to this).

·  the cost per unit breakdown.

·  The survival / rates of recovery for those ventilated.

 

I’d also like to enquire if there has been an uptake in the non-invasive units for the second wave of battling the pandemic.

 

Response:

I’m writing to you under the Freedom of Information Act (2000) to request information on the usage of certain types of Ventilator within your Trust, based on the models acquired during the ventilator challenge specifically relating to: 

the Penlon ventilators, 

 

The Breas Ventilators,

 

The Smiths Medical Ventilators,

 

and the CPAP non-invasive units. 

I’d like to know, if possible: 

How many of the various invasive models were used within your trust vs how many were ordered (the Penlon units being the most important with regards to this).

Since March 2020 we have ordered x23 non-invasive CPAP devices, prior to this we had 13 in use. This brings our total number of CPAP devices to 36 across the Trust. We have not ordered any, or used, the Penlon, Breas or Smiths ventilators.

The cost per unit breakdown.

15 CPAP devices, Stellar 150, cost £3,100 each

8 CPAP devices, Airvo 2, cost £2,300 each

The survival / rates of recovery for those ventilated.

Up to 31st August 2020 the critical care mortality rate for patients with COVID-19 infection was 61.4% – this includes both non-invasively ventilated and invasively ventilated patients.  Data split by mode of ventilation is not readily available.

 

From the 1st September 2020 to 31st December 2020 the critical care mortality rate for patients with COVID-19 infection was 60.2% – this includes both non-invasively ventilated and invasively ventilated patients.  Data split by mode of ventilation is not readily available.

 

These figures represent critical care outcomes only and are therefore not the same as survival in terms of discharge from hospital to home.

I’d also like to enquire if there has been an uptake in the non-invasive units for the second wave of battling the pandemic.

Non-invasive respiratory support has been used in Royal Bolton Hospital since the outset of the COVID-19 pandemic. 

 

Within critical care the choice of respiratory support is individually tailored to the patient’s clinical needs.

 

There has generally been a greater use of non-invasive therapies which has followed changes in national guidance.  Non-invasive respiratory therapies are also delivered within the specialist respiratory wards.